Innate Pharma S.A. - ADR

The momentum for this stock is not very good. Innate Pharma S.A. - ADR is not a good growth stock. Innate Pharma S.A. - ADR is not very popular among insiders. Innate Pharma S.A. - ADR is a mediocre stock to choose.

News

Innate Pharma S.A. (IPHA) Q2 2024 Earnings Call Transcript

Seeking Alpha: Transcripts Innate Pharma S.A. (IPHA) Q2 2024 Earnings Call Transcript...\n more…

Innate Pharma Reports First Half 2024 Business Update and Financial Results

Business Wire Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its consolidated financial results for the six months ended June 30, 2024. The...\n more…

Innate Pharma reports AstraZeneca presentation of results from NeoCOAST-2 study

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Innate Pharma SA:Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

Business Wire Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized...\n more…

Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update

Business Wire Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 p.m...\n more…

Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that Arvind Sood, EVP, President of US Operations, is to participate in the upcoming...\n more…